353 related articles for article (PubMed ID: 29709558)
1. Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial.
Kurokawa Y; Doki Y; Mizusawa J; Terashima M; Katai H; Yoshikawa T; Kimura Y; Takiguchi S; Nishida Y; Fukushima N; Iwasaki Y; Kaji M; Hirao M; Katayama H; Sasako M
Lancet Gastroenterol Hepatol; 2018 Jul; 3(7):460-468. PubMed ID: 29709558
[TBL] [Abstract][Full Text] [Related]
2. Five-year follow-up of a randomized clinical trial comparing bursectomy and omentectomy alone for resectable gastric cancer (JCOG1001).
Kurokawa Y; Doki Y; Mizusawa J; Yoshikawa T; Yamada T; Kimura Y; Takiguchi S; Nishida Y; Fukushima N; Cho H; Kaji M; Hirao M; Sasako M; Terashima M
Br J Surg; 2022 Dec; 110(1):50-56. PubMed ID: 36369984
[TBL] [Abstract][Full Text] [Related]
3. Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial.
Katai H; Mizusawa J; Katayama H; Morita S; Yamada T; Bando E; Ito S; Takagi M; Takagane A; Teshima S; Koeda K; Nunobe S; Yoshikawa T; Terashima M; Sasako M
Lancet Gastroenterol Hepatol; 2020 Feb; 5(2):142-151. PubMed ID: 31757656
[TBL] [Abstract][Full Text] [Related]
4. Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial.
Yoshikawa T; Terashima M; Mizusawa J; Nunobe S; Nishida Y; Yamada T; Kaji M; Fukushima N; Hato S; Choda Y; Yabusaki H; Yoshida K; Ito S; Takeno A; Yasuda T; Kawachi Y; Katayama H; Fukuda H; Boku N; Sano T; Sasako M
Lancet Gastroenterol Hepatol; 2019 Mar; 4(3):208-216. PubMed ID: 30679107
[TBL] [Abstract][Full Text] [Related]
5. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial.
Fujitani K; Yang HK; Mizusawa J; Kim YW; Terashima M; Han SU; Iwasaki Y; Hyung WJ; Takagane A; Park DJ; Yoshikawa T; Hahn S; Nakamura K; Park CH; Kurokawa Y; Bang YJ; Park BJ; Sasako M; Tsujinaka T;
Lancet Oncol; 2016 Mar; 17(3):309-318. PubMed ID: 26822397
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes after prophylactic bursectomy in patients with resectable gastric cancer: Final analysis of a multicenter randomized controlled trial.
Hirao M; Kurokawa Y; Fujita J; Imamura H; Fujiwara Y; Kimura Y; Takiguchi S; Mori M; Doki Y;
Surgery; 2015 Jun; 157(6):1099-105. PubMed ID: 25704429
[TBL] [Abstract][Full Text] [Related]
7. Survival benefit of bursectomy in patients with resectable gastric cancer: interim analysis results of a randomized controlled trial.
Fujita J; Kurokawa Y; Sugimoto T; Miyashiro I; Iijima S; Kimura Y; Takiguchi S; Fujiwara Y; Mori M; Doki Y
Gastric Cancer; 2012 Jan; 15(1):42-8. PubMed ID: 21573917
[TBL] [Abstract][Full Text] [Related]
8. Extensive peritoneal lavage with saline after curative gastrectomy for gastric cancer (EXPEL): a multicentre randomised controlled trial.
Yang HK; Ji J; Han SU; Terashima M; Li G; Kim HH; Law S; Shabbir A; Song KY; Hyung WJ; Kosai NR; Kono K; Misawa K; Yabusaki H; Kinoshita T; Lau PC; Kim YW; Rao JR; Ng E; Yamada T; Yoshida K; Park DJ; Tai BC; So JBY;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):120-127. PubMed ID: 33253659
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial.
Hamaguchi T; Shimada Y; Mizusawa J; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Takiguchi N; Yatsuoka T; Takii Y; Ojima H; Masuko H; Kubo Y; Mishima H; Yamaguchi T; Bando H; Sato T; Kato T; Nakamura K; Fukuda H; Moriya Y
Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):47-56. PubMed ID: 29079411
[TBL] [Abstract][Full Text] [Related]
10. Influence of bursectomy on operative morbidity and mortality after radical gastrectomy for gastric cancer: results of a randomized controlled trial.
Imamura H; Kurokawa Y; Kawada J; Tsujinaka T; Takiguchi S; Fujiwara Y; Mori M; Doki Y
World J Surg; 2011 Mar; 35(3):625-30. PubMed ID: 21161652
[TBL] [Abstract][Full Text] [Related]
11. Survival outcomes following laparoscopic versus open D3 dissection for stage II or III colon cancer (JCOG0404): a phase 3, randomised controlled trial.
Kitano S; Inomata M; Mizusawa J; Katayama H; Watanabe M; Yamamoto S; Ito M; Saito S; Fujii S; Konishi F; Saida Y; Hasegawa H; Akagi T; Sugihara K; Yamaguchi T; Masaki T; Fukunaga Y; Murata K; Okajima M; Moriya Y; Shimada Y
Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):261-268. PubMed ID: 28404155
[TBL] [Abstract][Full Text] [Related]
12. Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial.
Fujita S; Akasu T; Mizusawa J; Saito N; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Shiozawa M; Yamaguchi T; Moriya Y;
Lancet Oncol; 2012 Jun; 13(6):616-21. PubMed ID: 22591948
[TBL] [Abstract][Full Text] [Related]
13. Totally laparoscopic complete bursectomy and D2 lymphadenectomy in radical total gastrectomy: an outside bursa omentalis approach.
Zou L; Xiong W; Mo D; Chen G; He Y; Li H; Tan P; Wang W; Wan J
Surg Endosc; 2016 Sep; 30(9):4152. PubMed ID: 26675932
[TBL] [Abstract][Full Text] [Related]
14. D2 gastrectomy with versus without bursectomy for gastric cancer.
Kochi M; Fujii M; Kanamori N; Kaiga T; Mihara Y; Funada T; Tamegai H; Takayama Y; Yoshida N; Takayama T
Am J Clin Oncol; 2014 Jun; 37(3):222-6. PubMed ID: 22892432
[TBL] [Abstract][Full Text] [Related]
15. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial.
Songun I; Putter H; Kranenbarg EM; Sasako M; van de Velde CJ
Lancet Oncol; 2010 May; 11(5):439-49. PubMed ID: 20409751
[TBL] [Abstract][Full Text] [Related]
16. Bursectomy and non-bursectomy D2 gastrectomy for advanced gastric cancer, initial experience from a single institution in China.
Zhang WH; Chen XZ; Yang K; Liu K; Chen ZX; Zhang B; Zhou ZG; Hu JK
World J Surg Oncol; 2015 Dec; 13():332. PubMed ID: 26643472
[TBL] [Abstract][Full Text] [Related]
17. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
Tsuburaya A; Yoshida K; Kobayashi M; Yoshino S; Takahashi M; Takiguchi N; Tanabe K; Takahashi N; Imamura H; Tatsumoto N; Hara A; Nishikawa K; Fukushima R; Nozaki I; Kojima H; Miyashita Y; Oba K; Buyse M; Morita S; Sakamoto J
Lancet Oncol; 2014 Jul; 15(8):886-93. PubMed ID: 24954805
[TBL] [Abstract][Full Text] [Related]
18. Efficiency of bursectomy in patients with resectable gastric cancer: An updated meta-analysis.
Xiong B; Ma L; Huang W; Cheng Y; Luo H; Wang K
Eur J Surg Oncol; 2019 Aug; 45(8):1483-1492. PubMed ID: 30691723
[TBL] [Abstract][Full Text] [Related]
19. Short-term outcomes of complete mesocolic excision versus D2 dissection in patients undergoing laparoscopic colectomy for right colon cancer (RELARC): a randomised, controlled, phase 3, superiority trial.
Xu L; Su X; He Z; Zhang C; Lu J; Zhang G; Sun Y; Du X; Chi P; Wang Z; Zhong M; Wu A; Zhu A; Li F; Xu J; Kang L; Suo J; Deng H; Ye Y; Ding K; Xu T; Zhang Z; Zheng M; Xiao Y;
Lancet Oncol; 2021 Mar; 22(3):391-401. PubMed ID: 33587893
[TBL] [Abstract][Full Text] [Related]
20. Complete omentectomy and extensive lymphadenectomy with gastrectomy improves the survival of gastric cancer patients with metastases in the adjacent peritoneum.
Hagiwara A; Sawai K; Sakakura C; Shirasu M; Ohgaki M; Yamasaki J; Togawa T; Takahashi T
Hepatogastroenterology; 1998; 45(23):1922-9. PubMed ID: 9840177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
